Patent intelligence · US
US 7235534
Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )
Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )
Patent details — US 7235534
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 26, 2007
- Expiration
- Jun 21, 2027
- Applicant
- INSTITUT DE CARDIOLOGIE DE MONTREAL
- Claims
- 7
- CPC classes
- A61K, A61K38/00, A61K39/00, A61P
Quick answer
US 7235534 (Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )) is held by INSTITUT DE CARDIOLOGIE DE MONTREAL. Status: granted. Granted Jun 26, 2007. Expires Jun 21, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- INSTITUT DE CARDIOLOGIE DE MONTREAL
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K38/00, A61K39/00, A61P, A61P9/00, A61P9/10
More from INSTITUT DE CARDIOLOGIE DE MONTREAL
Related pharmaceutical patents in our USPTO index.
-
US 12419888
Methods of treating elevated plasma cholesterol
granted -
US 11844771
Methods of treating acute respiratory distress syndrome using colchicine
granted -
US 11795434
Engineered stem cells and cellular products produced and secreted by such cells, methods of preparing, and uses thereof
granted -
US 11639490
Device and method for producing and purifying exosomes
granted -
US 11529390
PCSK9 inhibitory polypolypeptides and methods of use
granted -
US 11400063
Early administration of low-dose colchicine after myocardial infarction
granted -
US 10788490
Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits
granted -
US 9789134
Agent for the selective adjustment of blood lipids
granted
Frequently asked questions
What is US patent 7235534?
US 7235534 (Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )) is held by INSTITUT DE CARDIOLOGIE DE MONTREAL. Status: granted. Granted Jun 26, 2007. Expires Jun 21, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7235534?
INSTITUT DE CARDIOLOGIE DE MONTREAL is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 7235534 expire?
Our index shows an expiration date of Jun 21, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.